<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173300</url>
  </required_header>
  <id_info>
    <org_study_id>GLY-000</org_study_id>
    <nct_id>NCT03173300</nct_id>
  </id_info>
  <brief_title>Natural History Study Protocol in PMM2-CDG (CDG-Ia)</brief_title>
  <official_title>Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycomine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycomine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)

      This is a natural history (observational) protocol designed to collect clinical and
      biological information in patients with PMM2-CDG (CDG-Ia).

      Data from this natural history study will be used to determine a set of clinical and
      biological parameters that will be used for primary and secondary endpoints in a later
      clinical trial with a new chemical entity, Lipo-M1P.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in this natural history study will be thoroughly examined for signs and
      symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging
      studies will be performed during a single consultation. Follow-up will occur every 6 months
      at a minimum, depending on the standard of care at the investigator's institution as well as
      the clinical status of the individual patient. All medical procedures are routine. No new
      therapy is offered as part of this study, and no change in the patients' routine therapy is
      dictated by this protocol. No randomization will be performed.

      Since no new therapy is offered as part of this study and no change in the patients' routine
      therapy is dictated by this protocol, only Serious Adverse Events potentially related to a
      procedure specifically requested (if any) by this natural history study will need to be
      reported to the Sponsor. However, all non-serious adverse events will be recorded in the
      natural history (observational) study CRF database, in order to be considered as a reference
      for the planned clinical trial to occur later on under a separate protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>collect clinical and biological information in patients with CDG-PMM2</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Phosphomannomutase 2 Deficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with PMM2-CDG, all ages
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/assent by the patient and/or their legally authorized representative

          -  Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests

          -  Willing and able to adhere to study requirements described in the protocol and
             consent/assent documents

        Exclusion Criteria:

          -  Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)

          -  Plan to use investigational drug during study participation

          -  Blood loss of &gt;250 mL or donated blood within 56 days, or donated plasma within 7
             days, of study screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Rioux MD, PhD / Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Glycomine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Jo Bagger / Sr. Director, Clinical Operations</last_name>
    <phone>+1 (858) 500-6621</phone>
    <email>mbagger@glycomine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chung Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans C Andersson, MD</last_name>
      <phone>504-988-5229</phone>
      <email>handers@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Ketchens, Study Coordinator</last_name>
      <phone>504-988-0645</phone>
      <email>jketchens@tulane.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Bohlen, Study Coordinator</last_name>
      <phone>507-293-7485</phone>
      <email>bohlen.sarah@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
      <phone>504-444-9386</phone>
      <email>morava-kozicz.eva@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Patterson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Nesom</last_name>
      <phone>267-426-1368</phone>
      <email>nesom@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Edmondson, MD, PhD</last_name>
      <phone>215-313-4607</phone>
      <phone_ext>22178</phone_ext>
      <email>edmondsona@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Can Ficicioglu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Leshinski</last_name>
      <phone>412-692-5232</phone>
      <email>angela.leshinski@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Vockley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lam, MD</last_name>
      <email>christina.lam@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Witters, MD, PhD</last_name>
      <email>peter.witters@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomas Honzik, MD, PhD</last_name>
      <email>tomas.honzik@vfn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necker Enfants-Malades Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale de Lonlay, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Barone, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mother and Child Institute (Instytut Matki i Dziecka)</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jolanta Sykut-Cegielska, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dulce Quelhas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Grunewald, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMM2-CDG</keyword>
  <keyword>CDG-Ia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

